ReviewHealth science reports2025
An Umbrella Review of Meta-Analyses on the Efficacy and Safety of Eltrombopag in Immune Thrombocytopenia.
Review in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Umbrella Review of Meta-Analyses on the Efficacy and Safety of Eltrombopag in Immune Thrombocytopenia.Health science reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Immune thrombocytopenia (ITP) is an autoimmune disorder with increased bleeding risk. Eltrombopag, an oral thrombopoietin receptor agonist, is widely used after corticosteroids or immunoglobulins. Multiple meta-analyses support its efficacy, yet safety concerns persist. We conducted an umbrella review to synthesize evidence on efficacy and safety across age groups. Methods: We searched PubMed, Scopus, and Web of Science through April 2025 for systematic reviews/meta-analyses on eltrombopag in ITP. Methodological quality was appraised using AMSTAR 2. Outcomes included platelet response, bleeding, and adverse events. We mapped primary trials across reviews to address overlap and qualitatively summarized findings; no new pooling was performed. Results: Nine meta-analyses met inclusion. Across adult/mixed populations, eltrombopag increased platelet response (e.g., RR ≈ 3.4, Conclusion: Eltrombopag is effective in raising platelet counts and reducing bleeding in ITP. Benefits appear to increase up to ~50 mg daily and plateau thereafter. Age-related variability and safety considerations support individualized dosing and vigilant follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.